Fate Therapeutics Announces Worldwide Collaboration With Janssen For Novel IPSC-derived Cell-Based Cancer Immunotherapies; Co. To Receive $50M Upfront And $50M Equity Investment And Eligible To Receive Up To $1.8B
Benzinga Newsdesk